Center for Medical Biotechnology
CMB in a nutshell
Science director: Nico Callewaert
At CMB, the focus lies on the development of new and innovative molecular tools and technologies to address human health problems. An emerging and fascinating research theme is the development and production of new biopharmaceuticals and vaccines. CMB researchers are working on new applications in tuberculosis research, cancer treatment and antiviral immunity, among others. Research at CMB pushes the boundaries of biomolecular/bioinformatics research and engineering. We also translate our new technologies and insights into widely applicable research tools, vaccines, diagnostics and pharmaceuticals.
Labs
Name
Function
VIB Group Leader / Expert
Extra info
VIB-UGent Center for Medical Biotechnology
Name
Function
VIB Group Leader / Expert
Extra info
VIB-UGent Center for Medical Biotechnology
Name
Function
VIB Group Leader / Expert
Extra info
VIB-UGent Center for Medical Biotechnology
Name
Function
VIB Group Leader / Expert
Extra info
VIB-UGent Center for Medical Biotechnology
Name
Function
VIB Group Leader / Expert
Extra info
VIB-UGent Center for Medical Biotechnology
Name
Function
VIB Group Leader / Expert
Extra info
VIB-UGent Center for Medical Biotechnology
Name
Function
VIB Group Leader / Expert
Extra info
VIB-UGent Center for Medical Biotechnology
Name
Function
VIB Group Leader / Expert
Extra info
VIB-UGent Center for Medical Biotechnology
Impact on society
Blood test for liver diseases
VIB, in collaboration with Helena Biosciences, is set to commercialize a comprehensive blood test called Glyco Liver Profile for chronic liver diseases, a condition affecting up to 29 million people in the EU. This non-invasive test allows medical professionals to diagnose and monitor liver inflammation, fibrosis, and cirrhosis, providing an accurate and personalized alternative to invasive techniques.
Read more
Improving liver disease diagnosis
Overcoming the main current diagnostic challenges in hepatology practice in the liver project.
Read more
Inhalable biologics to control respiratory infections
Developing pan-influenza neutralizing biologics to treat and prevent viral pneumonia in the Ibcori project.
Read more